The continuous stream of drug approvals by Chinese pharmaceutical companies should be a source of awe to any global innovation investor. There are multiple reasons that have led to the current point. However, one key contributor is China’s drug approval policy transformation, which is one of the most under-discussed and massively impactful policy narratives of […]
